Ghrelin Receptors Discovered in Human Hypothalamus and Pituitary Gland
Background
Ghrelin, often called the 'hunger hormone', is a peptide primarily produced in the stomach that plays a crucial role in regulating appetite, energy balance, and stimulating growth hormone (GH) release. While its primary receptor, the growth hormone secretagogue receptor (GHSR-1a), was known, its precise distribution and binding characteristics in key human brain regions like the hypothalamus (a control center for many bodily functions) and the pituitary gland (which produces GH) were not fully established. This study aimed to confirm and characterize specific ghrelin receptor binding sites in membranes from human hypothalamus and pituitary gland tissues.
Results
The study successfully identified specific, high-affinity, and saturable binding sites for 125I-labeled ghrelin in both human hypothalamic and pituitary membranes. In the hypothalamus, a robust binding site was characterized with a dissociation constant (Kd) of approximately 0.2-0.5 nM (nanomolar), indicating very strong binding affinity, and a maximal binding capacity (Bmax) of 50-80 fmol/mg protein (femtomoles per milligram of protein), signifying a substantial number of receptors. Similarly, pituitary membranes exhibited specific ghrelin binding with a Kd in the range of 0.3-0.6 nM and a Bmax of 30-60 fmol/mg protein, confirming direct receptor presence in this gland. The binding was shown to be highly specific, as unlabeled ghrelin effectively displaced 125I-labeled ghrelin with an IC50 (concentration causing 50% inhibition of binding) of approximately 1-2 nM, demonstrating a selective interaction with the ghrelin receptor. Other structurally unrelated peptides showed negligible displacement, further validating the specificity of the observed binding.
Why It Matters
This study provides critical direct evidence for the presence of ghrelin receptors in key human brain regions, specifically the hypothalamus and pituitary gland, which are central to regulating appetite, energy homeostasis, and growth hormone secretion. These findings solidify our understanding of ghrelin's physiological mechanisms in humans, confirming that these areas are direct targets for ghrelin's actions. This foundational knowledge is crucial because it could inform the development of novel therapeutic strategies targeting the ghrelin system for a range of metabolic and endocrine disorders, including obesity, cachexia (severe weight loss), and growth hormone deficiency. Future research could build upon these findings with functional studies in living systems, potentially leading to Phase I/II clinical trials for ghrelin receptor agonists or antagonists.